+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Fibromyalgia Therapeutics Market - Global Forecast 2026-2032- Product Image
Fibromyalgia Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

Fibromyalgia Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 180 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5887861
UP TO OFF until Dec 31st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Fibromyalgia Therapeutics Market is projected to reach USD 4.04 Billion in 2026. It is expected to continue growing at a CAGR of 5.66%, reaching USD 5.66 Billion by 2032.

Fibromyalgia therapeutics focus on improving chronic widespread pain, fatigue, sleep disturbance, cognitive symptoms, mood-related comorbidities, and functional impairment associated with fibromyalgia, a complex central sensitization condition recognized in international clinical frameworks. The therapeutic landscape includes approved pharmacologic options, clinically supervised off-label medicines, behavioral interventions, exercise-based care, sleep management, patient education, and multidisciplinary pain programs. Growing clinical attention to patient-reported outcomes, comorbidity screening, and individualized treatment pathways is strengthening demand for safer, evidence-based fibromyalgia treatment strategies. SEO-relevant themes shaping the field include fibromyalgia drugs, chronic pain therapeutics, non-opioid pain management, neuromodulation, digital therapeutics, cognitive behavioral therapy, and personalized pain medicine. The sector is also influenced by tighter scrutiny of opioid prescribing, increasing recognition of women’s health and pain equity, and rising adoption of integrated care models that combine pharmacological and non-pharmacological approaches.

Transformative Shifts in Fibromyalgia Therapeutics

The fibromyalgia therapeutics landscape is shifting from symptom suppression toward integrated, patient-centered disease management. Clinical guidance increasingly emphasizes education, graded physical activity, cognitive behavioral approaches, sleep optimization, and selective pharmacotherapy rather than reliance on a single intervention. Non-opioid pain management remains a defining priority as health systems respond to opioid-related harms and the limited role of opioids in fibromyalgia care. Advances in pain neuroscience are reframing fibromyalgia as a disorder involving central sensitization, altered pain processing, autonomic dysregulation, and overlapping mood and sleep disorders, which is encouraging multimodal treatment algorithms. Digital health tools, remote monitoring, telehealth-enabled pain clinics, and app-based behavioral support are improving continuity of care for patients who often experience delayed diagnosis and fragmented treatment. At the same time, payer and provider focus on real-world outcomes, adherence, tolerability, and functional improvement is raising expectations for therapies that demonstrate meaningful benefits in daily living, sleep quality, fatigue, and work participation.

Cumulative Impact of AI on Fibromyalgia Therapeutics

Artificial intelligence is becoming an important enabler in fibromyalgia therapeutics by supporting earlier recognition, individualized care planning, and more efficient clinical research. AI-enabled analytics can help identify symptom clusters, comorbidity patterns, medication response signals, and risk factors for poor treatment adherence by analyzing electronic health records, patient-reported outcomes, wearable sensor data, and digital pain diaries. In clinical development, machine learning can improve trial design by refining eligibility criteria, reducing heterogeneity, supporting decentralized data collection, and detecting responder subgroups within a condition known for variable symptom expression. In care delivery, AI-supported decision tools may assist clinicians in matching patients with appropriate combinations of pharmacologic treatment, cognitive behavioral therapy, sleep interventions, physical activity plans, rehabilitation, and mental health support. However, responsible use requires transparent algorithms, validation across diverse populations, privacy safeguards, and avoidance of bias in pain assessment, particularly because chronic pain conditions have historically been affected by gender, socioeconomic, and racial disparities in recognition and treatment.

Key Regional Insights for Fibromyalgia Therapeutics

Asia-Pacific is witnessing rising attention to fibromyalgia therapeutics as awareness of chronic pain disorders improves across urban health systems, particularly in China, Japan, India, South Korea, and Australia. Regional dynamics are shaped by uneven diagnosis rates, expanding rheumatology and pain medicine capacity, growing mental health integration, and increasing use of telehealth and digital symptom management to address access gaps. North America remains a highly active region for fibromyalgia treatment innovation due to established clinical recognition, broad use of multidisciplinary pain programs, strong patient advocacy, and continued movement toward non-opioid chronic pain care. Latin America is advancing through expanding specialist access in larger economies such as Brazil and Mexico, although underdiagnosis, uneven public reimbursement, and variability in access to behavioral care continue to influence treatment adoption. Europe benefits from strong clinical guideline frameworks, cross-border research collaboration, pharmacovigilance systems, and increasing integration of pharmacological care with physiotherapy, psychological interventions, and sleep management. The Middle East is seeing demand rise alongside expanding specialty care infrastructure, with Gulf health systems placing greater emphasis on chronic disease management, rehabilitation services, and digital healthcare. Africa faces significant barriers, including limited specialist availability, low public awareness, and competing health priorities, yet telemedicine, primary care training, and greater recognition of chronic pain syndromes are creating gradual opportunities for improved fibromyalgia care.

Key Group Insights for Fibromyalgia Therapeutics

ASEAN countries are developing fibromyalgia therapeutics access through expanding urban hospital networks, improving pain medicine awareness, and growing use of mobile health tools, though diagnostic consistency remains a challenge across diverse healthcare systems. The GCC is positioned around advanced healthcare infrastructure, rising investment in specialty clinics, and increasing digital health adoption, which supports integrated chronic pain management and rehabilitation-led approaches. The European Union provides a structured environment for fibromyalgia care through guideline-driven practice, pharmacovigilance standards, health technology assessment, and multidisciplinary care models that prioritize patient safety and functional outcomes. BRICS countries reflect a mixed but influential therapeutic environment, with large patient populations, expanding pharmaceutical access, growing digital health ecosystems, and increasing public health focus on chronic noncommunicable conditions, while variability in reimbursement and specialist availability affects uptake. G7 countries generally show stronger research intensity, established regulatory oversight, broader access to behavioral and rehabilitative services, and greater emphasis on non-opioid pain management. NATO member countries, many of which overlap with Europe and North America, demonstrate advanced clinical infrastructure and research collaboration capacity, supporting evidence generation, digital care adoption, and policy alignment around safer chronic pain treatment.

Key Country Insights for Fibromyalgia Therapeutics

The United States is a major center for fibromyalgia therapeutics due to high chronic pain awareness, established use of approved and off-label therapies, strong telehealth penetration, patient advocacy, and policy pressure to reduce inappropriate opioid reliance. Canada emphasizes multidisciplinary pain care, mental health integration, and guideline-informed approaches, although access to specialized pain services varies by province. Mexico and Brazil are strengthening fibromyalgia recognition through expanding private healthcare access, specialist networks, and chronic pain education, while public-sector constraints and underdiagnosis continue to affect care pathways. The United Kingdom supports evidence-based non-pharmacological intervention, pain education, and primary care-led management, while Germany and France benefit from robust healthcare systems, rheumatology expertise, structured reimbursement environments, and strong rehabilitation capacity. Russia, Italy, and Spain show increasing recognition of fibromyalgia within rheumatology and pain medicine, with ongoing emphasis on rehabilitation, sleep care, mental health support, and appropriate pharmacotherapy. China is advancing through hospital modernization, digital health scale, and growing awareness of chronic pain disorders, while India faces a dual environment of rising diagnosis in urban centers and persistent access gaps in lower-resource settings. Japan’s aging population, strong clinical infrastructure, and focus on quality-of-life outcomes shape fibromyalgia management, while Australia demonstrates mature multidisciplinary pain programs, primary care coordination, and digital health adoption. South Korea combines advanced healthcare technology, high digital engagement, and expanding pain management services, making it an important country for innovation in patient monitoring, telemedicine, and personalized chronic pain care.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize therapies and care models that address the full fibromyalgia symptom burden, including pain, fatigue, sleep disruption, cognitive dysfunction, mood symptoms, and reduced physical function. Development programs should incorporate validated patient-reported outcomes, real-world evidence, and subgroup analyses to identify patients most likely to benefit from specific interventions. Stakeholders should invest in non-opioid mechanisms, combination care pathways, digital therapeutics, remote monitoring, and adherence support tools that align with clinical guidelines and payer expectations. Partnerships with clinicians, patient organizations, academic groups, and digital health providers can improve education, diagnosis, and continuity of care. Healthcare innovators should also design inclusive research protocols that account for sex, age, ethnicity, comorbidities, and socioeconomic differences in pain experience. Regulatory and reimbursement strategies should emphasize measurable improvements in function, sleep, tolerability, safety, and quality of life rather than narrow pain-score reduction alone.

Research Methodology

This executive summary is developed using a secondary research approach centered on verified medical, regulatory, and public health sources, including peer-reviewed clinical literature, international disease classification references, clinical practice guidelines, pharmacovigilance resources, health agency publications, and real-world chronic pain care evidence. The methodology emphasizes data triangulation across clinical research, guideline statements, regional healthcare policy indicators, digital health adoption trends, and chronic pain management standards. Insights were evaluated for relevance to fibromyalgia therapeutics, non-opioid pain management, multidisciplinary care, artificial intelligence applications, and regional access dynamics. The analysis deliberately excludes market estimation, market sizing, market share, and market forecasting. Country, regional, and group-level perspectives were synthesized into narrative insights to support strategic understanding while maintaining evidence-based interpretation and avoiding unsupported commercial claims.

Conclusion

Fibromyalgia therapeutics are entering a more integrated, evidence-driven era shaped by pain neuroscience, non-opioid treatment priorities, digital health adoption, and growing use of artificial intelligence. The most resilient strategies will combine safe pharmacological options with behavioral therapy, exercise, sleep management, mental health support, rehabilitation, and continuous patient engagement. Regional differences in diagnosis, reimbursement, specialist access, and digital infrastructure will continue to influence adoption, while common global priorities include earlier recognition, personalized care, and measurable improvements in function and quality of life. Industry participants that invest in patient-centered evidence, inclusive research, responsible AI, and multidisciplinary delivery models will be best positioned to address the unmet needs of people living with fibromyalgia.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Fibromyalgia Therapeutics Market, by Drug Class
7.1. Introduction
7.2. Anticonvulsants
7.2.1. Branded
7.2.2. Generic
7.3. Selective Serotonin Reuptake Inhibitors
7.3.1. Branded
7.3.2. Generic
7.4. Serotonin And Norepinephrine Reuptake Inhibitors
7.4.1. Branded
7.4.2. Generic
7.5. Tricyclic Antidepressants
7.5.1. Branded
7.5.2. Generic
8. Fibromyalgia Therapeutics Market, by Route Of Administration
8.1. Introduction
8.2. Oral
8.3. Parenteral
8.4. Topical
9. Fibromyalgia Therapeutics Market, by Distribution Channel
9.1. Introduction
9.2. Online
9.3. Offline
10. Fibromyalgia Therapeutics Market, by End User
10.1. Introduction
10.2. Home Care
10.3. Hospital
10.4. Specialty Clinics
11. Fibromyalgia Therapeutics Market, by Region
11.1. Asia-Pacific
11.2. North America
11.3. Latin America
11.4. Europe
11.5. Middle East
11.6. Africa
12. Fibromyalgia Therapeutics Market, by Group
12.1. ASEAN
12.2. GCC
12.3. European Union
12.4. BRICS
12.5. G7
12.6. NATO
13. Fibromyalgia Therapeutics Market, by Country
13.1. United States
13.2. Canada
13.3. Mexico
13.4. Brazil
13.5. United Kingdom
13.6. Germany
13.7. France
13.8. Russia
13.9. Italy
13.10. Spain
13.11. China
13.12. India
13.13. Japan
13.14. Australia
13.15. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. FPNV Positioning Matrix, 2025
14.3. Market Concentration Analysis, 2025
14.3.1. Concentration Ratio (CR)
14.3.2. Herfindahl Hirschman Index (HHI)
14.4. Recent Developments & Impact Analysis, 2025
14.5. Product Portfolio Analysis, 2025
14.6. Benchmarking Analysis, 2025
15. Company Profiles
15.1. AbbVie Inc.
15.2. Amgen Inc.
15.3. Amicus Therapeutics, Inc.
15.4. Astellas Pharma Inc.
15.5. AstraZeneca PLC
15.6. Bayer AG
15.7. Biogen Inc.
15.8. BioMarin Pharmaceutical Inc.
15.9. Bristol-Myers Squibb Company
15.10. C. H. Boehringer Sohn AG & Co. KG
15.11. Eli Lilly and Company
15.12. Gilead Sciences, Inc.
15.13. GSK plc
15.14. Jazz Pharmaceuticals plc
15.15. Johnson & Johnson
15.16. Kyowa Kirin Co., Ltd.
15.17. Merck & Co., Inc.
15.18. Novartis AG
15.19. Pfizer Inc.
15.20. Regeneron Pharmaceuticals, Inc.
15.21. Roche Holding AG
15.22. Sanofi
15.23. Sarepta Therapeutics, Inc.
15.24. Takeda Pharmaceutical Company Limited
15.25. Teva Pharmaceutical Industries Ltd.
15.26. Vertex Pharmaceuticals Incorporated
15.27. Viatris Inc.
List of Figures
FIGURE 1. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 11. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 13. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 17. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 19. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 21. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ANTICONVULSANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL BRANDED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL BRANDED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL BRANDED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL GENERIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL GENERIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL GENERIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL SELECTIVE SEROTONIN REUPTAKE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL SELECTIVE SEROTONIN REUPTAKE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL SELECTIVE SEROTONIN REUPTAKE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL BRANDED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL BRANDED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL BRANDED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL GENERIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL GENERIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL GENERIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL BRANDED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL BRANDED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL BRANDED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL GENERIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL GENERIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL GENERIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL TRICYCLIC ANTIDEPRESSANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL TRICYCLIC ANTIDEPRESSANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL TRICYCLIC ANTIDEPRESSANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL BRANDED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL BRANDED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL BRANDED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL GENERIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL GENERIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL GENERIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL HOSPITAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL HOSPITAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL HOSPITAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 70. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 71. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 72. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 73. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 74. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 75. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 76. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 77. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 79. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 80. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 81. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 82. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 83. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 84. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 85. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 86. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 88. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 89. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 90. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 91. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 92. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 93. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 94. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 95. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 97. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 98. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 99. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 100. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 101. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 102. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 103. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 104. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 106. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 107. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 108. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 109. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 110. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 111. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 112. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 113. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 114. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 115. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 116. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 117. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 118. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 119. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 120. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 121. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 123. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 124. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 125. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 126. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 127. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 128. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 129. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 130. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 131. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 132. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 133. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 134. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 135. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 136. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 137. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 138. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 139. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 140. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 141. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 142. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 143. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 144. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 145. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 146. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 147. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 148. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 149. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 150. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 151. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 152. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 153. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 154. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 155. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 156. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 157. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 158. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 159. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 160. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 161. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 162. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 163. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 164. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 165. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 166. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 167. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 168. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 169. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 170. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 171. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 172. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 173. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 174. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 175. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 176. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 177. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 178. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 179. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 180. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 181. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 182. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 183. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 184. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 185. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 186. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 187. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 188. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 189. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 190. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 191. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 192. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 193. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 194. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 195. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 196. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 197. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 198. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 199. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 200. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 201. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 202. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 203. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 204. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 205. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 206. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 207. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 208. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 209. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 210. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 211. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 212. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 213. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 214. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 215. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 216. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 217. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 218. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 219. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 220. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 221. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 222. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 223. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 224. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 225. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 226. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 227. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 228. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 229. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 230. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 231. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 232. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 233. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 234. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 235. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 236. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 237. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 238. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 239. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 240. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 241. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 242. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 243. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 244. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 245. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 246. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 247. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 248. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 249. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 250. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 251. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 252. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 253. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 254. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 255. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 256. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 257. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 258. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 259. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 260. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 261. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 262. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 263. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 264. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 265. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 266. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 267. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 268. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 269. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 270. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 271. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 272. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 273. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 274. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 275. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 276. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 277. INDIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 278. INDIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 279. INDIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 280. INDIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 281. INDIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 282. INDIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 283. INDIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 284. INDIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 285. INDIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 286. JAPAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 287. JAPAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 288. JAPAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 289. JAPAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 290. JAPAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 291. JAPAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 292. JAPAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 293. JAPAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 294. JAPAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 295. AUSTRALIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 296. AUSTRALIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 297. AUSTRALIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 298. AUSTRALIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 299. AUSTRALIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 300. AUSTRALIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 301. AUSTRALIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 302. AUSTRALIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 303. AUSTRALIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 304. SOUTH KOREA FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 305. SOUTH KOREA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 306. SOUTH KOREA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 307. SOUTH KOREA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 308. SOUTH KOREA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 309. SOUTH KOREA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 310. SOUTH KOREA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 311. SOUTH KOREA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 312. SOUTH KOREA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 313. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 314. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • Amicus Therapeutics, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • BioMarin Pharmaceutical Inc.
  • Bristol-Myers Squibb Company
  • C. H. Boehringer Sohn AG & Co. KG
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GSK plc
  • Jazz Pharmaceuticals plc
  • Johnson & Johnson
  • Kyowa Kirin Co., Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi
  • Sarepta Therapeutics, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Incorporated
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages180
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 4.04 Billion
Forecasted Market Value ( USD ) by 2032 $ 5.66 Billion
Compound Annual Growth Rate5.6%
Regions CoveredGlobal
No. of Companies Mentioned27

Related Topics

Related Reports

Fibromyalgia Therapeutics - Global Strategic Business Report - Product Image

Fibromyalgia Therapeutics - Global Strategic Business Report

  • Report
  • 263 Pages
  • Global
From
Fibromyalgia Treatment Market - Global Strategic Business Report - Product Image

Fibromyalgia Treatment Market - Global Strategic Business Report

  • Report
  • 276 Pages
  • Global
From
Fibromyalgia Treatment Market Report 2026 - Product Image

Fibromyalgia Treatment Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Digital Therapeutics for Fibromyalgia Market Report 2026 - Product Image

Digital Therapeutics for Fibromyalgia Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Fibromyalgia: Market View - Product Image

Fibromyalgia: Market View

  • Report
  • 114 Pages
  • Global
From

About the Fibromyalgia Drug Market

The Fibromyalgia Drug market is a subset of the Immune Disorders Drugs market, which includes treatments for a variety of conditions related to the immune system. Fibromyalgia is a chronic disorder characterized by widespread musculoskeletal pain, fatigue, and tenderness in localized areas. Fibromyalgia drugs are used to reduce pain, improve sleep, and reduce fatigue. Commonly prescribed drugs include antidepressants, anticonvulsants, and muscle relaxants. Other treatments include physical therapy, cognitive behavioral therapy, and lifestyle modifications. The Fibromyalgia Drug market is highly competitive, with a number of companies offering treatments. Some of the major players in the market include Pfizer, Eli Lilly, Merck, and Novartis. Other companies include AbbVie, Allergan, and Teva Pharmaceuticals. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.